All Outputs (2)

MMP-10 is overexpressed, proteolytically active and a potential target for therapeutic intervention in human lung carcinomas (2004)
Journal Article
Gill, J., Kirwan, I., Seargent, J., Martin, S., Tijani, S., Anikin, V., …Loadman, P. (2004). MMP-10 is overexpressed, proteolytically active and a potential target for therapeutic intervention in human lung carcinomas. Neoplasia, 6(6), 777-785. https://doi.org/10.1593/neo.04283

Matrix metalloproteinase (MMP)-mediated degradation of the extracellular matrix is a major factor for tumor development and expansion. This study analysed MMP-10 protein expression and activity in human lung tumors of various grade, stage, and type t... Read More about MMP-10 is overexpressed, proteolytically active and a potential target for therapeutic intervention in human lung carcinomas.

NAD(P)H:Quinone oxidoreductase-1 C609T polymorphism analysis in human superficial bladder cancers: relationship of genotype status to NQO1 phenotype and clinical response to Mitomycin C (2004)
Journal Article
Basu, S., Brown, J., Flannigan, G., Gill, J., Loadman, P., Martin, S., …Phillips, R. (2004). NAD(P)H:Quinone oxidoreductase-1 C609T polymorphism analysis in human superficial bladder cancers: relationship of genotype status to NQO1 phenotype and clinical response to Mitomycin C. International Journal of Oncology, 25(4), 921-928

NAD(P)H:Quinone oxidoreductase-1 (NQO1) has been implicated in the bioreductive activation of the clinically active anticancer drug Mitomycin C (MMC) and a polymorphic variant of NQO1 which lacks functional enzyme activity (NQO1*2) has been linked wi... Read More about NAD(P)H:Quinone oxidoreductase-1 C609T polymorphism analysis in human superficial bladder cancers: relationship of genotype status to NQO1 phenotype and clinical response to Mitomycin C.